MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$9,933K
Net Income
-$18,856K
Net Profit Margin
-189.83%
EPS
-$2.93
Unit: Thousand (K) dollars
Revenue Breakdown
INDOCINProducts
Sympazan
SPRIXNasal Spray
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Total revenues
9,933
13,544
49,459
29,222
Cost of sales
2,711
3,266
13,654
10,677
Research and development expenses
454
486
379
387
Selling, general and administrative expenses
19,434
13,135
16,930
16,960
Change in fair value of contingent consideration
-
552*
-276
-
Amortization of intangible assets
5,804
5,803
5,594
9,233
Impairment of intangible assets
-
-552*
1,700
-
Restructuring charges
0
2,600
0
0
Total costs and expenses
28,403
25,290
37,981
37,257
Loss from operations
-18,470
-11,746
11,478
-8,035
Gain on assertio therapeutics divestiture
-
-4*
0
-8,174
Interest expense
775
768*
770
768
Interest income
469
606
664
675
Other loss
-35
166
26
6
Total other expense
-341
0
-80
-8,261
Net loss before income taxes
-18,811
-11,746
11,398
-16,296
Income tax expense
-
-
-
100
Income tax expense
45
181
-47
56
Net loss and comprehensive loss
-18,856
-11,927
11,445
-16,352
Basic EPS
-2.93
0.045
0.12
-0.17
Diluted EPS
-2.93
0.044
0.11
-0.17
Basic Average Shares
6,434,000
-262,280,000
96,245,000
95,970,000
Diluted Average Shares
6,434,000
-272,549,000
106,514,000
95,970,000
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Net loss and
comprehensive loss
-$18,856K
(-39.25%↓ Y/Y)
INDOCINProducts
$3,446K
(-37.84%↓ Y/Y)
Sympazan
$2,580K
(18.40%↑ Y/Y)
SPRIXNasal Spray
$1,370K
(-13.78%↓ Y/Y)
Product Other
$1,009K
(-71.67%↓ Y/Y)
ROLVEDON
$493K
Net loss before
income taxes
-$18,811K
(-41.48%↓ Y/Y)
Income tax expense
$45K
(-81.63%↓ Y/Y)
Product
$8,898K
(-65.77%↓ Y/Y)
Product And Service
Other
$600K
Royalty
$435K
(-11.94%↓ Y/Y)
Loss from operations
-$18,470K
(-39.58%↓ Y/Y)
Total other expense
-$341K
(-441.27%↓ Y/Y)
Total revenues
$9,933K
(-62.50%↓ Y/Y)
Interest income
$469K
(-34.86%↓ Y/Y)
Total costs and
expenses
$28,403K
(-28.49%↓ Y/Y)
Interest expense
$775K
(1.31%↑ Y/Y)
Other loss
-$35K
(-94.44%↓ Y/Y)
Selling, general and
administrative expenses
$19,434K
(-11.56%↓ Y/Y)
Amortization of intangible
assets
$5,804K
(-37.14%↓ Y/Y)
Cost of sales
$2,711K
(-65.18%↓ Y/Y)
Research and development
expenses
$454K
(3.65%↑ Y/Y)
Buy us a coffee
Assertio Holdings, Inc. (ASRT)
Assertio Holdings, Inc. (ASRT)